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Abstract
Objective: Reperfusion after ischemia may contribute to loss of myocardial function and increase in infarct size. Scavenging of reactive
oxygen species (ROS) by glutathione (GSH) and inhibition of the sodium-proton-exchanger by cariporide are both capable of reducing
myocardial reperfusion injury. We tested the efficacy of both agents applied regionally into the myocardium immediately before reperfusion.
Methods: Neonatal rat cardiomyocytes (NRCMs) were exposed to either hypoxia (H, 8 h)/reoxygenation (R, 1 h) or H2O2 (300 AM) in the
presence or absence of GSH (10 mg/ml). In pigs (n=5 per group), percutaneous LAD occlusion was performed for 60 min. Application of
GSH (250 mg/kg) and/or cariporide (1 mg/kg) was achieved by pressure-regulated retroinfusion of the anterior cardiac vein draining the
ischemic area starting 5 min before reopening of the occluded LAD. Seven days later, subendocardial segment shortening (SES) was
analyzed by sonomicrometry. Infarct size was determined by methylene-blue staining of the non-ischemic area and tetrazolium red staining of
the viable myocardium in the area at risk (AAR). Results: NRCM incubated with GSH (10 mg/ml) survived H/R or H2O2 (0.3 mM) to a
larger extent than untreated cells. In pigs, infarct size of untreated hearts (51F6% of the AAR) was not significantly altered by GSH or
cariporide retroinfusion alone (41F3% and 42F6%). In contrast, combined retroinfusion of cariporide and GSH significantly reduced
infarct size (29F3%). SES of the infarcted area was improved only after cariporide/GSH retroinfusion as compared to untreated hearts.
Additional systemic application of CD18-antibody IB4 (1.5 mg/kg) did not alter infarct size or SES in comparison to GSH/cariporide
retroinfusion alone. Conclusion: Timely application of GSH scavenging ROS and cariporide targeting ion imbalance provides
cardioprotection to the postischemic heart, which is superior to either treatment alone. The lack of an effect of additional IB4 treatment may
indicate that GSH/cariporide retroinfusion itself affects leukocyte-dependent reperfusion injury.
D 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Keywords: Reperfusion injury; Infarct size; NHE; ROS
1. Introduction
Reperfusion of an occluded coronary artery, established
as standard treatment in the case of myocardial infarction,
may induce arrhythmias [1], myocardial stunning [2] and
microcirculatory flow disturbances such as no reflow [1,3]
in the postischemic myocardium. Cellular mechanisms
mediating these pathophysiological phenomena include for-
mation of reactive oxygen species (ROS) [4] by myocytes
[5], endothelial cells [6] and adherent leukocytes [7].I n
addition, myocyte ion imbalance leading to e.g. calcium
overload and hypercontracture [8], is involved in the loss of
postischemic myocardial organ function. Consistently, ther-
apeutic approaches to prevent or reduce myocardial reper-
fusion injury included application of reactive oxygen
species scavengers and sodium-proton-exchanger inhibitors
(NHE-I).
However, enzymatic elimination of reactive oxygen
species by superoxide dismutase and catalase lacked in vivo
efficacy in preclinical large animal models [9–11] although
myocyte protection was achieved in vitro [12]. Alternative-
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 ly, supplementation of physiological ROS scavengers such
as GSH is an attractive option, since intracellular GSH
levels decrease rapidly after ROS-exposure. In isolated
perfused rat hearts, GSH supply during ischemia offers
cardioprotection during reperfusion, as long as a certain
length of ischemia is not exceeded [13]. For this purpose,
however, high concentrations of GSH are required, e.g. 5
mM in an isolated rat heart model [13] or 800 mg/kg in a pig
model [14]. GSH supplementation at this scale appears
difficult to achieve in patients, a limitation potentially
overcome by targeted application, such as pressure-regulat-
ed retroinfusion into the ischemic myocardial region.
Beyond ROS-induced detriment, evidence suggests that
myocyte ion imbalance is a major cause of myocardial
ischemia–reperfusion injury. As demonstrated in adult car-
diomyocytes [15], the sodium hydrogen exchanger (NHE)
inhibitor cariporide protects against post-hypoxic myocyte
contracture. In addition, several animal studies revealed a
cardioprotective effect of NHE inhibitors in large animal
models when applied before or early in the course of
ischemia [16–18], as opposed to application at the onset
of reperfusion [18]. In contrast, systemic application of
NHE-inhibitors in patients with acute coronary syndromes
did not improve postischemic myocardial infarct size or
patient outcome [19,20].
Taken together, despite experimental data suggesting an
effect of either scavenging reactive oxygen species or
attenuating ion imbalance in the course of myocardial
ischemia–reperfusion, the limited efficacy of systemic ap-
plication seems to hinder a detectable success in clinical
trials. Recently, we demonstrated that selective, pressure-
regulated retroinfusion is a efficient regional approach of
drug, gene or protein application into the ischemic myocar-
dium [21–23]. In these studies, selective pressure-regulated
retroinfusion into a coronary vein (AIV) draining the LAD-
area was performed during occlusion of the (LAD), an
approach also used in patients [24]. Using this application
method, we now studied regional pharmacological therapy
with GSH and/or cariporide at the end of ischemia and
during the onset of reperfusion (a protocol feasible in
patients, Kupatt and Boekstegers, unpublished results).
Moreover, since GSH and cariporide are widely accepted
as acting on myocyte compartment, we studied whether
additional protection of the endothelial compartment—by a
CD18 antibody inhibiting endothelium–leukocyte interac-
tion—would provide enhanced cardioprotection, or if an
overlap of the therapeutic targets of GSH/cariporide treat-
ment and CD18 antibody would exist.
2. Materials and methods
2.1. Materials
Cariporide was a gift of Aventis (Frankfurt, Germany),
GSH was purchased from Roche (Milano, Italy). All
further chemicals were from Sigma (Deisenhofen, Ger-
many), if not stated otherwise. The CD18 antibody IB4
was raised from a hybridoma cell line from ATCC (New
York, USA). Animals were purchased from Oberschleis-
sheim, Germany.
2.2. Cell culture experiments
Rat neonatal cardiomyocytes were prepared as previous-
ly published [25]. Thereafter, cells were plated in 12-well
plates and subjected to GSH (10 mg/ml) and/or cariporide
(100 Ag/ml) incubation. Myocytes were challenged by
oxidative stress with two protocols: either, after pretreatment
with GSH (10 mg/ml, 1 h) and gentle washing, cells were
subjected to normoxia (9 h) or hypoxia (8 h) and reoxyge-
nation (1 h 95% O2 and 5% CO2) (Fig. 1A,B). Alternatively,
cells were exposed to H2O2 (0.3 mmol/l, 12 h) in the
presence of GSH (10 mg/ml) with or without cariporide
(100 Ag/ml) (Fig. 1C,D). A score was established to
semiquantitatively evaluate myocyte function (0=no con-
tracting cell, 1=singular contracting cells, 2=majority of
cells contracting at reduced rate, 3=homogenous contrac-
tion at rate of normoxic control cells). Viability of cells was
assessed by Trypan blue exclusion, whereas Trypan blue-
positive cells were counted as dead.
2.3. Animal experimental protocol
The care of the animals and all experimental procedures
conform with the German and NIH animal legislation
guidelines and were approved by the local animal care
and use committee (AZ 2531-7/01). All pig experiments
were conducted at the Institute for Surgical Research of the
University of Munich. German farm pigs (n=5 per exper-
imental group) were anesthetized and instrumented as
described previously [26]. The external jugular vein and
the carotid artery of the right side were cannulated and
appropriate sheaths (8 F) were placed.
2.4. Ischemia
A balloon was placed in the LAD distal to the bifurcation
of the first diagonal branch, and inflated with 4 atm (0.41
MPa). Correct localisation of the coronary occlusion and
patency of the first diagonal branch was ensured by injec-
tion of contrast agent. At 30 min of ischemia, systemic
CD18-antibody IB4 infusion was performed for 15 min (1.5
mg/kg bodyweight), where indicated, thus targeting circu-
lating leukocytes potentially recruited to the postischemic
myocardium.
2.5. Retroinfusion
As described in detail previously [27], the retroinfusion
catheter was advanced into the anterior interventricular vein
(AIV) draining the parenchyma perfused by the LAD. After
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 assessment of the individual systolic occlusion pressure of
the venous system, retroinfusion pressure was set 20 mm Hg
above the latter. In retrogradely treated groups, at 55 min of
ischemia, continuous pressure-regulated retroinfusion of
isothermic Tyrode solution (50 ml/min) containing GSH
(250 mg/kg) and, where indicated, coinfusion of cariporide
(1 mg/kg), was begun. Retroinfusion was interrupted for 30
s for drawing of blood samples at indicated time points (cf.
Fig. 2) and otherwise continued for 10 min, overlapping
with the restoration of blood flow for 5 min.
Blood samples were quickly drawn from coronary osti-
um and anterior interventricular vein in a random order up
to 30 min of reperfusion. Thereafter, venous and arterial
catheters and sheaths were withdrawn, the vessels ligated
and suture of the muscle and the skin performed. Animals
were brought back to the animal facility where they were
fed with water and nutrition ad libitum.
At the end of the experiment (day 7 after ischemia),
animals were brought back to the OR, anesthetized and
instrumented. After hemodynamic measurements, sternot-
omy was performed and the pericardium was removed.
Ultrasonic crystals were placed 1 cm (area at risk) and 4
cm distal to the balloon occlusion site. Each pair was inserted
with its axis perpendicular to the LAD. Another pair of
crystals was inserted in the Cx perfusion area. Subendocar-
dial segment shortening (SES) was performed under resting
heart rate as well as at 120 and 150/min atrial pacing (for 1
min each), as described before [27].
2.6. Infarct size determination
Before arrest of the heart, 20 ml of methylene blue were
injected in the left ventricle during external ligation of the
Fig. 2. GSH-levels of coronary arterial (LAD) and coronary venous (AIV)
blood samples drawn before LAD occlusion (pre), mid-ischemic (30 min I),
after the onset of retroinfusion of GSH (58 min I), during retroinfusion and
reperfusion (2 min R), and during reperfusion after cessation of
retroinfusion (10 min R and 30 min R). As expected, GSH elevation was
observed in coronary venous and, to a lesser extent, in coronary artery
samples during GSH-retroinfusion. Twenty-five minutes after the end of
retroinfusion, coronary venous levels were still >100-fold above pre-
ischemic levels (§=p<0.05 vs. pre-ischemic levels, #=p<0.05 vs. time-
matched arterial level (n=4).
Fig. 1. (A) GSH-content of isolated rat neonatal cardiomyocytes (NRCMs) without or with GSH treatment for 60 min (10 mg/ml) and subsequent normoxia (9
h) or hypoxia (8 h) and reoxygenation (1 h). GSH levels of the cell pellets were increased after GSH-exposure. (B) Myocyte cell integrity after 8 h hypoxia and
1 h of reoxygenation (H/R) in untreated NRCMs (left panel) in comparison to GSH-preincubation (right panel). Representative example of three independent
cell preparations after Trypan blue staining. (C) NRCMs incubated with GSH (10 mg/ml) with or without cariporide (100 Ag/ml) were exposed to H2O2 (0.3
mM) for 12 h and the contractility was scored (cf. Materials and methods). Quantification of four independent cell preparations. (D) Viability of NRCMs
(Trypan blue exclusion) after identical H2O2 stimulation without or with GSH exposure. (*=p<0.05 vs. control, §=p<0.05 vs. H2O2).
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 LAD at the previous occlusion site, thus staining the non-
ischemic area. After heart excision, the infarct size was
determined by pressure-controlled injection (80–100 mm
Hg) of 15 ml of 10% tetrazolium red into the LAD, staining
non-infarcted area at risk intensely red, whereas infarcted
tissue remained pale. Thereafter, the left ventricle was cut
into slices of 5 mm thickness, which were subjected to digital
photography. Image processing of the digital pictures with
trace measurements (SigmaScan) provided volume of infarct
region, area at risk and total LVarea for each slice [28].
2.7. GSH measurements
Blood samples from the coronary artery (LAD) and
coronary vein (AIV) were analyzed for GSH content. In
addition, tissue samples from a control region (Cx perfu-
sion area), the area at risk and the infarcted area were
taken at 1 h of reperfusion (Fig. 3). Total soluble gluta-
thione (GSH+GSSG) was measured in medium, cell
pellets, plasma and homogenates from freeze-clamped
hearts. Blood samples of 500 Al were collected for
determination of GSH and GSSG in plasma. For GSSG
analysis, an aliquot (200 Al) of blood was mixed immedi-
ately with 200 Alo f1 0m MN-ethylmaleimide (NEM) in
100 mM phosphate buffer (pH 6.5) containing 17.5 mM
EDTA. The remaining blood was centrifuged at full speed
for 1 min. An aliquot (100 Al) of plasma was pipetted into
100 Al sulfosalicylic acid (5%) for determination of total
glutathione. To separate GSSG from NEM and NEM-GSH
adducts, an aliquot of NEM treated plasma was passed
through a Sep-PakC18 cartridge (Waters, Framingham,
MA) followed by 1 ml of 100 mM phosphate buffer (pH
7.5). GSSG in the eluates and total glutathione in plasma
and acidic homogenates were determined by an enzymatic
test as described previously [29]. GSH plasma concentra-
tions were calculated as the difference between total GSH
and GSSG.
2.8. Statistical methods
The results are given as meanFSEM. Statistical analysis
was performed using one-way analysis of variance
(ANOVA). Whenever a significant effect was obtained with
ANOVA, we performed multiple comparison tests between
the groups using Student–Newman–Keul’s procedure
(SPSS statistical program). Differences between groups
were considered significant for p<0.05.
3. Results
3.1. GSH-content of rat neonatal myocytes
As depicted in Fig. 1A, GSH content of untreated
neonatal rat cardiomyocytes (NRCM) was not significant-
ly different after either normoxia (9 h) or hypoxia (8 h)
and reoxygenation (1 h). However, an increased GSH
content of the cell pellet was found after exposure to
GSH (1 h, 10 mg/ml) before the hypoxia/reoxygenation
challenge.
In the given cell culture model, in vitro analysis of the
ROS scavenging potential of GSH was performed by
exposure to H2O2 (0.3 mmol/l). As depicted in Fig. 1C,
regular contractions of the myocytes almost completely
ceased 12 h after exposure to H2O2. However, concomitant
presence of GSH preserved residual contractile function, a
phenomenon further increased by co-application of caripor-
ide (100 Ag/ml). Consistently, after H2O2 exposure, the
proportion of lethally injured (Trypan blue-positive)
NRCMs was limited by GSH (Fig. 1D).
3.2. GSH-content of plasma and tissue samples in vivo
Coronary venous and arterial GSH levels were assessed
during the course of GSH retroinfusion. Compared to
control levels (2–3 AM), retroinfusion of GSH instanta-
neously increased coronary venous levels >1000-fold (cf.
Fig. 2). This level was sustained up to 5 min after cessation
of GSH-retroinfusion (=10 min reperfusion). Concomitant
coronary arterial levels of GSH were increased to a signif-
icantly lower level than coronary venous levels (cf. Fig. 2).
Of note, 25 min after cessation of retroinfusion (=30 min
reperfusion) coronary venous GSH levels, declining from
peak values, were still >150-fold elevated above untreated
samples, however, not differing from arterial GSH levels.
Tissue samples of hearts (Fig. 3) reperfused for 1 h after
ischemia revealed that GSH content in the infarcted region
of untreated hearts was substantially reduced in comparison
to GSH content of the non-ischemic RCx perfusion area
(0.18F0.05 vs. 0.91F0.13 Amol/g tissue). However, after
GSH retroinfusion, we detected no significant GSH defi-
ciency in the infarct region in comparison to the normoxic
control region.
Fig. 3. Tissue content of GSH in a non-ischemic control area (Cx perfusion
area) and the infarcted area in hearts explanted after 60 min of ischemia and
60 min of reperfusion (n=3 hearts). Whereas infarcted tissue displays a
significant loss of GSH compared to non-ischemic RCx-perfusion area,
GSH supplementation provided similar GSH levels in the control and
infarct area.
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 3.3. Infarct size
At day 7 of reperfusion, infarct size of control hearts was
51F5% of the area at risk, a proportion not significantly
changed by systemic infusion of GSH/cariporide (Fig. 4A).
GSH retroinfusion tended to decrease infarct size, however,
missing statistical significance (41F3%) similar to caripor-
ide retroinfusion alone (42F6%). The combination of GSH
and cariporide retroinfusion significantly reduced infarct
size to 29F3% (p<0.02).
3.4. Regional myocardial function
To assess myocardial function in the region exposed to
ischemia and reperfusion, sonomicrometry was performed
in a standardized manner in the infarcted and non-infarcted
area at risk as well as in the non-ischemic CX perfusion
area. As depicted in Fig. 4C, subendocardial segment
shortening (SES) of the infarcted area was severely reduced
to <50% of the non-ischemic area in all groups under
resting conditions. In hearts without treatment or with GSH
retroinfusion alone or systemic GSH/cariporide application,
SES tended to further decline at higher heart rates (pacing at
120 and 150/min), whereas retroinfusion of GSH and
cariporide combined preserved SES in the infarcted region
under these conditions.
In the area at risk, regional myocardial function was well-
preserved at rest (Fig. 4D). As expected, pacing revealed a
decreased functional reserve (57F15% at 150/min) in
hearts subjected to ischemia and reperfusion without treat-
ment. No loss of regional function was observed when
GSH/cariporide retroinfusion was applied.
3.5. Impact of CD18 blockade (IB4)
Since GSH and cariporide are known protectors of the
myocyte compartment, we assessed the therapeutic potential
of additional leukocyte inhibition by application of a CD18
antibody. We therefore infused IB4 at 30 min of ischemia in a
dose of 1.5 mg/kg bodyweight. Time course studies revealed
that at the given dose IB4 blocked >99% of the MAC-1, with
50% inhibition present at 4 h (data not shown). Thus, IB4
application appeared suitable for inhibition of early over-
whelming inflammation after ischemia and reperfusion.
In fact, IB4 displayed a distinct reduction of infarct size
at day 7 (38F4%), although no significant improvement of
Fig. 4. (A) Infarct size was assessed as the ratio of the infarcted area to the
area at risk (AAR). Compared to untreated controls, systemic application of
GSH and cariporide (GSH Cari S) did not significantly reduce the infarcted
area, similarly to retroinfusion of GSH (GSH R) or cariporide (Cari R)
alone. In contrast, combined retroinfusion of GSH and cariporide (GSH
Cari R) substantially decreased the infarct extension. (B) AAR as of the
total LV revealed no difference in infarct size in all groups. (C)
Subendocardial segment shortening (SES) in the infarcted area (percentage
of the RCx perfusion area) was reduced in untreated control hearts, and was
unaltered by GSH retroinfusion alone (GSH R) or systemic GSH/cariporide
infusion (GSH Cari S), whereas GSH/cariporide retroinfusion (GSH Cari
R) improved SES in the infarcted region at 120 and 150/min pacing rate.
(D) SES in the area at risk of the same experimental groups. At 150/min,
untreated hearts displayed a loss of SES (compared to baseline), whereas
GSH/cariporide retroinfusion preserved regional myocardial function.
(n=5;#=p<0.05 vs. control hearts, §=p<0.05 vs. baseline).
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 regional myocardial function occurred. Of note, combining
IB4 infusion with GSH/cariporide retroinfusion did not
extend the effect of either IB4 or GSH/cariporide treatment
(Figs. 4 and 5) significantly.
4. Discussion
In the present study, we used a pig model of 60 min LAD
occlusion and 7-day reperfusion to investigate the cardio-
protective effect of regional application of GSH and car-
iporide into the ischemic myocardium. We took advantage
of a novel percutaneous retrograde delivery system targeting
GSH and cariporide to the ischemic myocardium. Blood
sample analysis revealed a rapid increase of GSH in the
coronary venous blood, which exceeded coronary artery
levels more than 6-fold, indicating effective regional supply
of the pharmacologic agents. With this application strategy,
we could demonstrate for the first time that the combination
of GSH and cariporide retroinfusion decreased infarct size
and improved regional function of the area at risk, although
the application-to-reperfusion interval comprised a short
interval (5 min). Of note, retroinfusion of GSH/cariporide
combined provided postischemic cardioprotection which
was not achieved by one agent alone nor via systemic
application of both (Fig. 4A–C). The additional application
of the CD18 antibody IB4 did not induce a further protec-
tive effect.
During postischemic reperfusion, one major sources of
reactive oxygen species (ROS) are mitochondrial enzymes
of the myocytes [30]. ROS might injure myocytes, e.g. by
mitochondrial cytochrome c release [31–33], associated
with myocyte apoptosis. Myocyte protection against oxi-
dative stress was achieved by GSH supplementation in rat
neonatal myocytes challenged by H2O2 (Fig. 1C,D) or
hypoxia/reoxygenation (Fig. 1A,B). Here, cell survival as
well as cell morphology and function (contraction) was
preserved to a larger extent after GSH exposure. Of note,
GSH was capable of reducing cellular detriment induced
by hypoxia/reoxygenation although GSH incubation (1 h)
was interrupted with the onset of hypoxia (Fig. 1A,B).
Similar results have been obtained with adult cardiomyo-
cytes in cell culture [34]. In vivo, retroinfusion of GSH was
able to compensate for the early loss of GSH in the
infarcted area (at 1 h of reperfusion), similar to results of
other in vivo studies in pigs [14,35].H o w e v e r ,G S H
application alone did not suffice to significantly reduce
infarct size in our study. This observation might point to
Fig. 5. (A) Infarct size after GSH/cariporide retroinfusion (GSH Cari R)
was not significantly differing from infarct size after anti CD18 antibody
IB4 infusion. No additional effect was found after combination of both
treatments. (B) No difference was found in AAR to LV ratio of the three
groups. (C,D) SES of the infarct area (C) or the AAR (D) displayed
unaltered levels after either GSH/cariporide retroinfusion or IB4 infusion or
both.
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 the depth of ischemia, since cardioprotection by 5 mM
GSH after 20 and 30 min of hypoxia was lost after 50 min
of hypoxia in isolated rat hearts [13]. On the other hand,
the cardioprotective effect of endogenous GSH shown by
depletion strategies in rats [36], dogs [37] and pigs [14]
was exclusively achieved after pre-ischemic GSH-depletion
in each study. This therapeutic time frame is reflected by
the cardioprotective effect of GSH after supplementation
throughout ischemia in vivo [35]. In the present study, late
ischemic GSH retroinfusion, although rapidly increasing
local GSH plasma levels (Fig. 2) as well as GSH tissue
content (Fig. 3), did not exert significant cardioprotection,
despite a trend towards smaller infarct size (Fig. 4A). This
lack of therapeutic efficacy in vivo cannot be attributed to
inefficient distribution of the agent retroinfused into the
ischemic region (cf. Fig. 2), as opposed to systemic
application. More likely, the depth of 1 h ischemia (cf.
Ref. [13]) as well as detriment occurring early during
ischemia might have prevented a more pronounced effect
of GSH retroinfusion.
Unfortunately, clinical therapy of acute myocardial in-
farction most often faces an ischemic time of varying length,
which has to be limited by rapid reperfusion. This scenario
excludes pharmacological treatment early during limited
ischemia, as obviously required for GSH to be effective.
Since a further increase of GSH did not appear practical, we
sought to extend cardioprotection by combination of GSH
and cariporide. The different mechanisms of action of
cariporide, e.g. prevention of calcium overload, suggested
that an overlap with the ROS-scavenger GSH might be
limited, although both agents are capable of protecting
myocytes [34,38]. In fact, despite a lack of significant
cardioprotection achieved by retroinfusion of cariporide
alone, the combination with GSH retroinfusion provided a
substantial reduction of infarct size and regional myocardial
dysfunction (Fig. 4). Noteworthy, the cardioprotection was
achieved by retroinfusion into the ischemic myocardium not
earlier than 5 min before reopening of the occluded coro-
nary artery. Rather than covering the ischemic period, our
regional treatment approach was targeted at the onset of
reperfusion.
As a common denominator, GSH and cariporide are
widely viewed as preferentially protecting the myocyte
compartment. To test if GSH/cariporide application leaves
the endothelium unprotected against postischemic dysfunc-
tion, we applied a CD18 antibody (IB4), which was able to
reduce infarct size (Fig. 4) by virtue of inhibiting leukocyte
adhesion on the endothelium, as demonstrated before [22].
Co-application of GSH/cariporide and IB4 did not further
limit reperfusion injury in terms of infarct size and regional
function. This finding indicates that endothelial protection is
also a feature of GSH/cariporide treatment, as suggested by
recent studies [39–41]. E.g. the antiinflammatory properties
of resting endothelium, such as moderate nitric oxide release
[4] or strictly limited adhesion molecule expression [42] are
typically lost after ROS exposure. Both, however, are
maintained by GSH [41,43] and cariporide [44], enabling
less PMN accumulation in the infarct area of the GSH/
cariporide retroinfused hearts (data not shown). Moreover,
cariporide appears to decrease PMN activation after stimu-
lation with ROS [45].
In summary, the present study demonstrates that selective
retroinfusion of GSH and cariporide provides an effective
and timely approach to limiting postischemic myocardial
reperfusion injury. This approach proved to be superior to
therapy with either agent alone or systemic venous appli-
cation of both. Moreover, an overlap with endothelial
protection is suggested by the lack of additional CD18
blockade. These results have prompted the initiation of a
clinical study in patients with acute myocardial infarction,
who are currently being treated with GSH/cariporide retro-
infusion 5 min before the onset of reperfusion, as outlined
above.
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